Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
IARC Monographs, Volume 91
IARC
ISBN-13    9789283212911 ISBN-10    9283212916
Order Number    17200091   
Price    CHF    55.00 / US$    66.00 Developing countries:    CHF    38.50
English     2007        537   pages
Summary
Table of contents
Related Publications
Translation(s) available
Promotion flyer
 
 
   Add to your order
 
 
Summary
Oral contraceptives for family planning worldwide have revolutionized the reproductive lives of millions of women since their introduction in the 1960s. Later on, a variety of side-effects including cardiovascular diseases was recognized. In response to these concerns, new generations of combined oral contraceptives were developed that featured lower dose of estrogen and newer, more potent progestogens. The effectiveness and ease of use of combined hormonal contraceptives suggest that they will continue to be used to a significant extent in the future.

This ninety-first volume of IARC Monographs contains evaluations of the carcinogenic hazard to humans of combined estrogen-progestogen contraceptives and combined estrogen-protestogen menopausal therapy. The hormonal drugs reviewed in this volume involve co-administration of an estrogen and a progestogen. Studies that did not provide information on the use of combined estrogen-progestogen agents are not reviewed. It should also be noted that this volume reviews only studies that are publicly available and therefore does not include pharmaceutical test results that are not in the public domain.

The evaluations developed in this volume identify specific forms of cancer for which the risk is increased or decreased by combined estrogen-progestogen contraceptives and provide information that will help address the health concerns and well-being of hundred of millions of women worldwide.